<DOC>
	<DOC>NCT02496052</DOC>
	<brief_summary>To estimate the efficacy and safety of dried biological amnion graft after hysteroscopic lysis of intrauterine adhesions.</brief_summary>
	<brief_title>The Efficacy and Safety of the Dried Biological Amnion Graft in Patients With Intrauterine Adhesions</brief_title>
	<detailed_description>Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>age 2040 years； previously diagnostic hysteroscopy confirmed adhesion score &gt;5， according to the American Fertility Society （AFS）classification of IUA； complains of menstruation disorder and reproductive dysfunction； informed consent. premature menopause, presence of other intrauterine lesions (e.g. polyps, myoma, septa), and presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders, severe kidney and liver diseases), adhesions limited to the lower uterine cavity or the cervical canal.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>amnion graft</keyword>
	<keyword>New biological barrier system</keyword>
</DOC>